UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 16, 2012
_______________________________
ONCOLOGIX TECH, INC
(Exact name of registrant as specified in its charter)
_______________________________
| Nevada | 000-15482 | 86-1006416 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |
PO Box 8832 Grand Rapids, MI 49518-8832
(Address
of Principal Executive Offices) (Zip Code)
(616) 977-9933
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.02. Unregistered Sales of Equity Securities
On October 16, 2012, the Company sold 1,000,000 shares of its common stock to a non-related accredited investor at $0.02 per share. The sale resulted in gross proceeds to the Company of $20,000. These shares are exempt from registration pursuant to SEC Regulation D.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ONCOLOGIX TECH, INC.
| Date: October 17, 2012 | Oncologix Tech, Inc. | |
| By | /s/ Anthony Silverman | |
| Name: Anthony Silverman Title: President |
||
| Date: October 17, 2012 | Oncologix Tech, Inc. | |
| By | /s/ Michael A. Kramarz | |
| Name: Michael A. Kramarz Title: Chief Financial Officer |
||